View ValuationCareRx 将来の成長Future 基準チェック /06CareRxの収益は年間54.6%で減少すると予測されていますが、年間収益は年間4%で増加すると予想されています。EPS は年間12.5%で減少すると予想されています。主要情報-54.6%収益成長率-12.51%EPS成長率Consumer Retailing 収益成長10.0%収益成長率4.0%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日11 May 2026今後の成長に関する最新情報Breakeven Date Change • Mar 12Forecast breakeven date pushed back to 2025The 8 analysts covering CareRx previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 76% per year to 2024. The company is expected to make a profit of CA$1.96m in 2025. Average annual earnings growth of 86% is required to achieve expected profit on schedule.Breakeven Date Change • May 13Forecast breakeven date pushed back to 2024The 7 analysts covering CareRx previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 69% per year to 2023. The company is expected to make a profit of CA$2.40m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 9 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$3.86m in 2022. Average annual earnings growth of 124% is required to achieve expected profit on schedule.Breakeven Date Change • May 14Forecast to breakeven in 2022The 7 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2021. The company is expected to make a profit of CA$880.5k in 2022. Average annual earnings growth of 107% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • May 11CareRx Corporation announces Quarterly dividend, payable on July 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on July 09, 2026, ex-date on June 23, 2026 and record date on June 23, 2026.お知らせ • Apr 28CareRx Corporation to Report Q1, 2026 Results on May 06, 2026CareRx Corporation announced that they will report Q1, 2026 results After-Market on May 06, 2026お知らせ • Mar 17CareRx Corporation, Annual General Meeting, May 28, 2026CareRx Corporation, Annual General Meeting, May 28, 2026.お知らせ • Mar 10CareRx Corporation announces Quarterly dividend, payable on April 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on April 09, 2026, ex-date on March 19, 2026 and record date on March 19, 2026.お知らせ • Feb 25CareRx Corporation to Report Q4, 2025 Results on Mar 04, 2026CareRx Corporation announced that they will report Q4, 2025 results After-Market on Mar 04, 2026お知らせ • Dec 17CareRx Corporation announces Quarterly dividend, payable on January 21, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on January 21, 2026, ex-date on December 23, 2025 and record date on December 23, 2025.お知らせ • Oct 24CareRx Corporation to Report Q3, 2025 Results on Nov 03, 2025CareRx Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025お知らせ • Sep 17CareRx Corporation announces Quarterly dividend, payable on October 15, 2025CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on October 15, 2025, ex-date on September 23, 2025 and record date on September 23, 2025.お知らせ • Jul 21CareRx Corporation to Report Q2, 2025 Results on Jul 30, 2025CareRx Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025お知らせ • May 01CareRx Corporation to Report Q1, 2025 Results on May 07, 2025CareRx Corporation announced that they will report Q1, 2025 results at 7:00 AM, US Eastern Standard Time on May 07, 2025お知らせ • Mar 25CareRx Corporation, Annual General Meeting, Jun 05, 2025CareRx Corporation, Annual General Meeting, Jun 05, 2025.お知らせ • Feb 26CareRx Corporation to Report Q4, 2024 Results on Mar 05, 2025CareRx Corporation announced that they will report Q4, 2024 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2025Reported Earnings • Nov 10Third quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.025 loss in 3Q 2023)Third quarter 2024 results: CA$0.006 loss per share (improved from CA$0.025 loss in 3Q 2023). Revenue: CA$92.8m (down 1.0% from 3Q 2023). Net loss: CA$360.0k (loss narrowed 75% from 3Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Oct 31CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024CareRx Corporation announced that they will report Q3, 2024 results at 7:00 AM, Eastern Standard Time on Nov 08, 2024お知らせ • Sep 05CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024CareRx Corporation announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024. Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto.Reported Earnings • Aug 09Second quarter 2024 earnings released: CA$0.023 loss per share (vs CA$0.033 profit in 2Q 2023)Second quarter 2024 results: CA$0.023 loss per share (down from CA$0.033 profit in 2Q 2023). Revenue: CA$92.0m (down 2.7% from 2Q 2023). Net loss: CA$1.38m (down 173% from profit in 2Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.お知らせ • Aug 02CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024CareRx Corporation announced that they will report Q2, 2024 results at 7:00 AM, US Eastern Standard Time on Aug 08, 2024お知らせ • May 30CareRx Corporation Announces Board ChangesCareRx Corporation announced that as part of the Company's commitment to Board refreshment and to realign Board functions to match the Company's strategic focus on operational performance, Kevin Dalton, Chairman of the Board for the last six years, will be retiring as Chairman effectively immediately. Mr. Dalton will be succeeded by Jeff Watson, a current independent director of the Board. Mr. Dalton will be stepping into the role as Chair of the Compensation, Nominating and Governance Committee in place of Maria Perrella, who will continue to remain Chair of the Audit Committee. Mr. Watson has served on the Board of CareRx since 2023 and brings over three decades of experience in the healthcare industry, having most recently served as the President and CEO of Apotex from 2018 to 2023. Mr. Watson currently represents SK Capital Partners on two of their portfolio company boards for Apotex and Woodstock Sterile Solutions, and has previously served on numerous other boards, including as a board member and Chair of the Association for Accessible Medicines (AAM), Chair of the Canadian Generic Pharmaceutical Association (CGPA), and former Chair of the US Healthcare Distribution Alliance's (HDA) knowledge partner, the HDA Research Foundation.お知らせ • May 15CareRx Corporation Announces CFO TransitionCareRx Corporation announced that Andrew Mok will step down as Chief Financial Officer effective June 7, 2024, to pursue another employment opportunity. The Company is undertaking a search for a new CFO. Davide Pernarella, currently Vice President, Business Planning and Analysis at CareRx, will assume the role of Interim Chief Financial Officer following Mr. Mok's departure. Mr. Pernarella has worked at CareRx for over seven years in various roles with increasing responsibility, and has an intimate knowledge of the financial and business affairs of the Company. Prior to joining CareRx, he held roles in the Transaction Services and Assurance groups at KPMG Canada. Mr. Pernarella is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Commerce degree from the Rotman School of Management at the University of Toronto.Reported Earnings • May 12First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.039 loss in 1Q 2023)First quarter 2024 results: CA$0.009 loss per share (improved from CA$0.039 loss in 1Q 2023). Revenue: CA$89.7m (down 1.8% from 1Q 2023). Net loss: CA$517.0k (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.お知らせ • Mar 15CareRx Corporation, Annual General Meeting, May 28, 2024CareRx Corporation, Annual General Meeting, May 28, 2024.お知らせ • Mar 08CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023CareRx Corporation reported goodwill and intangible assets impairment of $710,000 for the fourth quarter ended December 31, 2023.Reported Earnings • Mar 08Full year 2023 earnings released: CA$94.25 loss per share (vs CA$0.72 loss in FY 2022)Full year 2023 results: CA$94.25 loss per share. Revenue: CA$370.7m (down 2.9% from FY 2022). Net loss: CA$5.41m (loss narrowed 84% from FY 2022). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe.お知らせ • Mar 01CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024CareRx Corporation announced that they will report Q4, 2023 results at 7:00 AM, US Eastern Standard Time on Mar 07, 2024New Risk • Nov 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$9.1m net loss in 2 years). Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€51.9m market cap, or US$57.0m).New Risk • Nov 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 25% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$9.1m net loss in 2 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€62.6m market cap, or US$66.8m).Reported Earnings • Nov 10Third quarter 2023 earnings released: CA$0.025 loss per share (vs CA$0.038 loss in 3Q 2022)Third quarter 2023 results: CA$0.025 loss per share (improved from CA$0.038 loss in 3Q 2022). Revenue: CA$93.8m (down 3.7% from 3Q 2022). Net loss: CA$1.44m (loss narrowed 19% from 3Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Nov 02CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023CareRx Corporation announced that they will report Q3, 2023 results at 7:00 AM, US Eastern Standard Time on Nov 08, 2023Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: CA$0.033 (vs CA$0.53 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.033 (up from CA$0.53 loss in 2Q 2022). Revenue: CA$94.5m (down 2.5% from 2Q 2022). Net income: CA$1.88m (up CA$27.0m from 2Q 2022). Profit margin: 2.0% (up from net loss in 2Q 2022). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.お知らせ • Aug 04CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023CareRx Corporation announced that they will report Q2, 2023 results at 7:00 AM, US Eastern Standard Time on Aug 10, 2023Board Change • Jun 08Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 07Carerx Corporation Announces Director ChangesCareRx Corporation appointed Puneet Khanna and Jeff Watson as directors. Company announced that Matt Hills did not stand for re-election.Reported Earnings • May 10First quarter 2023 earnings released: CA$0.039 loss per share (vs CA$0.059 loss in 1Q 2022)First quarter 2023 results: CA$0.039 loss per share (improved from CA$0.059 loss in 1Q 2022). Revenue: CA$91.4m (down 1.9% from 1Q 2022). Net loss: CA$2.15m (loss narrowed 22% from 1Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 12Forecast breakeven date pushed back to 2025The 8 analysts covering CareRx previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 76% per year to 2024. The company is expected to make a profit of CA$1.96m in 2025. Average annual earnings growth of 86% is required to achieve expected profit on schedule.Reported Earnings • Mar 10Full year 2022 earnings released: CA$0.72 loss per share (vs CA$0.65 loss in FY 2021)Full year 2022 results: CA$0.72 loss per share (further deteriorated from CA$0.65 loss in FY 2021). Revenue: CA$381.7m (up 45% from FY 2021). Net loss: CA$34.4m (loss widened 51% from FY 2021). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 19CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,963,000 Price\Range: CAD 2.7 Discount Per Security: CAD 0.162Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 10Third quarter 2022 earnings released: CA$0.038 loss per share (vs CA$0.11 loss in 3Q 2021)Third quarter 2022 results: CA$0.038 loss per share (improved from CA$0.11 loss in 3Q 2021). Revenue: CA$97.4m (up 37% from 3Q 2021). Net loss: CA$1.78m (loss narrowed 55% from 3Q 2021). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 16Second quarter 2022 earnings released: CA$0.53 loss per share (vs CA$0.28 loss in 2Q 2021)Second quarter 2022 results: CA$0.53 loss per share (down from CA$0.28 loss in 2Q 2021). Revenue: CA$96.9m (up 95% from 2Q 2021). Net loss: CA$25.1m (loss widened 196% from 2Q 2021). Over the next year, revenue is forecast to grow 7.5%, compared to a 7.7% growth forecast for the Consumer Retailing industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Jun 08President recently sold €171k worth of stockOn the 1st of June, David Murphy sold around 50k shares on-market at roughly €3.41 per share. This was the largest sale by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.Breakeven Date Change • May 13Forecast breakeven date pushed back to 2024The 7 analysts covering CareRx previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 69% per year to 2023. The company is expected to make a profit of CA$2.40m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule.Board Change • May 03Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Mar 19Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: CA$0.65 loss per share (up from CA$0.90 loss in FY 2020). Revenue: CA$262.6m (up 62% from FY 2020). Net loss: CA$22.7m (loss widened 25% from FY 2020). Revenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 46%, compared to a 7.0% growth forecast for the retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 11Third quarter 2021 earnings released: CA$0.11 loss per share (vs CA$0.28 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$71.3m (up 56% from 3Q 2020). Net loss: CA$3.93m (loss narrowed 39% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 9 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$3.86m in 2022. Average annual earnings growth of 124% is required to achieve expected profit on schedule.Reported Earnings • Aug 11Second quarter 2021 earnings released: CA$0.28 loss per share (vs CA$0.75 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$49.7m (up 25% from 2Q 2020). Net loss: CA$8.49m (loss narrowed 40% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Executive Departure • Jun 08Director Lyle Oberg has left the companyOn the 5th of June, Lyle Oberg's tenure as Director ended after 1.5 years in the role. We don't have any record of a personal shareholding under Lyle's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 2.88 years.Executive Departure • Jun 08Director Peter Brown has left the companyOn the 5th of June, Peter Brown's tenure as Director ended after less than a year in the role. We don't have any record of a personal shareholding under Peter's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 2.88 years.Breakeven Date Change • May 14Forecast to breakeven in 2022The 7 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2021. The company is expected to make a profit of CA$880.5k in 2022. Average annual earnings growth of 107% is required to achieve expected profit on schedule.Reported Earnings • May 14First quarter 2021 earnings released: CA$0.21 loss per share (vs CA$0.37 profit in 1Q 2020)The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$44.9m (up 47% from 1Q 2020). Net loss: CA$5.87m (down 209% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 2% per year.Reported Earnings • Mar 12Full year 2020 earnings released: CA$0.90 loss per share (vs CA$4.16 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$162.2m (up 30% from FY 2019). Net loss: CA$18.2m (loss narrowed 60% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 15% per year.Analyst Estimate Surprise Post Earnings • Mar 12Revenue misses expectationsRevenue missed analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 29%, compared to a 1.6% growth forecast for the Consumer Retailing industry in Germany.Is New 90 Day High Low • Feb 13New 90-day high: €3.16The company is up 17% from its price of €2.70 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.48 per share.お知らせ • Feb 04+ 1 more updateCareRx Corporation announced that it has received CAD 6.244997 million in funding from Yorkville Asset Management Inc., and other investorOn February 3, 2021, CareRx Corporation (TSX:CRRX) closed the transaction. The company issued 1,469,411 shares for gross proceeds of CAD 6,244,996.75 in the transaction.お知らせ • Jan 28+ 1 more updateCareRx Corporation announced that it expects to receive CAD 4.999998 million in funding from Yorkville Asset Management Inc., and another investorCareRx Corporation (TSX:CRRX) announced a non-brokered private placement of 1,176,470 common shares at a price of CAD 4.25 per share for gross proceeds of CAD 4,999,998 on January 27, 2021. The transaction will include participation from certain funds managed by returning investor Yorkville Asset Management Inc. and returning individual investor Jack Shevel. The transaction is expected to close on or about February 3, 2021 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange.Is New 90 Day High Low • Jan 28New 90-day high: €2.90The company is up 14% from its price of €2.54 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.22 per share.Is New 90 Day High Low • Dec 15New 90-day low: €2.22The company is down 21% from its price of €2.80 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.13 per share.お知らせ • Dec 03CareRx Corporation Enters Multi-Year Pharmacy Services Agreement with an Ontario- Based Seniors Home OperatorCareRx Corporation announced that it has entered into a multi-year pharmacy services agreement with an Ontario- based seniors home operator. The new contract, which commences in January 2021, will add approximately 1,100 new retirement and long-term care residents across 13 seniors housing communities, and is expected to be serviced through CareRx's existing infrastructure.Is New 90 Day High Low • Nov 27New 90-day low: €2.44The company is down 10.0% from its price of €2.72 on 28 August 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.14 per share.Analyst Estimate Surprise Post Earnings • Nov 07Revenue misses expectationsRevenue missed analyst estimates by 0.6%. Over the next year, revenue is forecast to grow 35%, compared to a 2.3% growth forecast for the Consumer Retailing industry in Germany.Reported Earnings • Nov 07Third quarter 2020 earnings released: CA$0.28 loss per shareThe company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$45.6m (up 45% from 3Q 2019). Net loss: CA$6.41m (loss widened 146% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 33% per year.お知らせ • Nov 03CareRx Corporation Announces Appointment of Puneet Khanna as Senior Vice President, Corporate DevelopmentCareRx Corporation announced that Puneet Khanna has joined the company as Senior Vice President, Corporate Development. Most recently, Mr. Khanna was Chief Executive Officer of MED e-care Healthcare Solutions Inc.お知らせ • Oct 29CareRx Corporation to Report Q3, 2020 Results on Nov 05, 2020CareRx Corporation announced that they will report Q3, 2020 results at 5:00 PM, Eastern Standard Time on Nov 05, 2020Recent Insider Transactions • Oct 01Insider recently bought €56k worth of stockOn the 29th of September, Ryan Stempfle bought around 20k shares on-market at roughly €2.78 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €55k more in shares than they have sold in the last 12 months.お知らせ • Aug 01CareRx Corporation to Report Q2, 2020 Results on Aug 06, 2020CareRx Corporation announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020お知らせ • Jul 30Centric Health Corporation (TSX:CHH) completed the acquisition of Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others.Centric Health Corporation (TSX:CHH) entered into a share purchase agreement to acquire Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others for CAD 35.4 million on March 23, 2020. As per the terms, consideration will be payable in CAD 8 million of cash and issuance of 125 million common shares at closing. The consideration also includes CAD 8 million of deferred consideration, comprised of CAD 4 million of deferred consideration due 12 months following closing, and CAD 4 million of consideration payable under a vendor take-back note due 18 months following closing, each of which is to be paid in cash or in certain circumstances common shares and an earn-out consideration of up to CAD 5 million payable in cash if certain performance targets are achieved over the next two years. Centric Health entered into binding commitment letters with Crown Capital Partners Inc. and Yorkville Asset Management Inc. pursuant to which Crown Capital and Yorkville are expected to advance credit facilities up to CAD 42 million to Centric Health to refinance its existing senior and subordinated credit facilities and fund the cash closing price of the transaction, CAD 7 million will be used for acquisition. In the event the transaction does not close in certain circumstances, a termination fee of CAD 1 million may be payable by the Centric Health in cash or, in certain circumstances, common shares. Bruce Moody and the Remedy's Rx Specialty Pharmacy team will join to the Centric. As part of the Transaction, Moody will receive the right to nominate two Directors to the Centric's Board of Directors under certain circumstances and will be entitled to other customary governance rights, including pre-emptive rights and registration rights. RHI generated revenue of approximately CAD 60 million for the 12-month period ended September 30, 2019. The transaction is subjected to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals and the consent of Centric Health shareholders. Under applicable Toronto Stock Exchange policies, the Centric Health is required to obtain shareholder approval for the transaction. As of April 23, 2020, Centric Health Corporation has obtained conditional approval of the transaction from the Toronto Stock Exchange and written consents from the requisite number of shareholders required to approve the transaction. The transaction is expected to close in the second quarter of 2020. As per filing on April 23, 2020, closing of the transaction will occur during the first or second week of May 2020. Origin Merchant Partners and BDO Canada LLP acted as the financial advisers to Centric Health, and NewPoint Capital Partners acted as the financial adviser to RHI. Centric Health Corporation (TSX:CHH) completed the acquisition of Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others on May 7, 2020. Jeff May will join Centric Health as its new Chief Operating Officer. Bruce Moody, Founder and former principal shareholder and Chief Executive Officer of Remedy’s RX specialty pharmacy, has been appointed as Centric Health's Board of Directors today and Peter Brown as appointed as a Board observer and will be nominated for election as a Director at Centric Health’s 2020 Annual General Meeting.業績と収益の成長予測DB:29C1 - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028415830N/A312/31/2027406826N/A612/31/20263856163373/31/2026375272230N/A12/31/2025370262331N/A9/30/202536602130N/A6/30/2025366-22332N/A3/31/2025367-42836N/A12/31/2024367-53038N/A9/30/2024366-63138N/A6/30/2024367-72734N/A3/31/2024369-42332N/A12/31/2023371-51927N/A9/30/2023374-62533N/A6/30/2023378-73038N/A3/31/2023380-341629N/A12/31/2022382-34922N/A9/30/2022384-34-411N/A6/30/2022358-36-510N/A3/31/2022311-20-18N/A12/31/2021263-2307N/A9/30/2021212-2127N/A6/30/2021187-24-6-3N/A3/31/2021177-29-20N/A12/31/2020162-18-20N/A9/30/2020148-50-3-1N/A6/30/2020134-47-20N/A3/31/2020126-34-12N/A12/31/2019125-46N/A6N/A9/30/2019122-19N/A3N/A6/30/2019119-20N/A4N/A3/31/2019117-39N/A9N/A12/31/2018119-35N/A7N/A9/30/201885-27N/A14N/A6/30/201897-23N/A12N/A3/31/2018110-3N/A15N/A12/31/2017122-4N/A16N/A9/30/2017168-6N/A14N/A6/30/2017170-3N/A24N/A3/31/2017170-13N/A10N/A12/31/2016167-18N/A2N/A9/30/2016166-21N/A6N/A6/30/2016166-34N/A3N/A3/31/2016164-30N/A20N/A12/31/2015161-35N/A29N/A9/30/201527-47N/A28N/A6/30/201560-48N/A22N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 29C1の収益は今後 3 年間で減少すると予測されています (年間-54.6% )。収益対市場: 29C1の収益は今後 3 年間で減少すると予測されています (年間-54.6% )。高成長収益: 29C1の収益は今後 3 年間で減少すると予測されています。収益対市場: 29C1の収益 ( 4% ) German市場 ( 6.8% ) よりも低い成長が予測されています。高い収益成長: 29C1の収益 ( 4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 29C1の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 09:28終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CareRx Corporation 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Kyle McPheeATB CormarkKyle McPheeATB Cormark Historical (Cormark Securities)Doug CooperBeacon Securities Limited8 その他のアナリストを表示
Breakeven Date Change • Mar 12Forecast breakeven date pushed back to 2025The 8 analysts covering CareRx previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 76% per year to 2024. The company is expected to make a profit of CA$1.96m in 2025. Average annual earnings growth of 86% is required to achieve expected profit on schedule.
Breakeven Date Change • May 13Forecast breakeven date pushed back to 2024The 7 analysts covering CareRx previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 69% per year to 2023. The company is expected to make a profit of CA$2.40m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 9 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$3.86m in 2022. Average annual earnings growth of 124% is required to achieve expected profit on schedule.
Breakeven Date Change • May 14Forecast to breakeven in 2022The 7 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2021. The company is expected to make a profit of CA$880.5k in 2022. Average annual earnings growth of 107% is required to achieve expected profit on schedule.
お知らせ • May 11CareRx Corporation announces Quarterly dividend, payable on July 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on July 09, 2026, ex-date on June 23, 2026 and record date on June 23, 2026.
お知らせ • Apr 28CareRx Corporation to Report Q1, 2026 Results on May 06, 2026CareRx Corporation announced that they will report Q1, 2026 results After-Market on May 06, 2026
お知らせ • Mar 17CareRx Corporation, Annual General Meeting, May 28, 2026CareRx Corporation, Annual General Meeting, May 28, 2026.
お知らせ • Mar 10CareRx Corporation announces Quarterly dividend, payable on April 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on April 09, 2026, ex-date on March 19, 2026 and record date on March 19, 2026.
お知らせ • Feb 25CareRx Corporation to Report Q4, 2025 Results on Mar 04, 2026CareRx Corporation announced that they will report Q4, 2025 results After-Market on Mar 04, 2026
お知らせ • Dec 17CareRx Corporation announces Quarterly dividend, payable on January 21, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on January 21, 2026, ex-date on December 23, 2025 and record date on December 23, 2025.
お知らせ • Oct 24CareRx Corporation to Report Q3, 2025 Results on Nov 03, 2025CareRx Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025
お知らせ • Sep 17CareRx Corporation announces Quarterly dividend, payable on October 15, 2025CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on October 15, 2025, ex-date on September 23, 2025 and record date on September 23, 2025.
お知らせ • Jul 21CareRx Corporation to Report Q2, 2025 Results on Jul 30, 2025CareRx Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025
お知らせ • May 01CareRx Corporation to Report Q1, 2025 Results on May 07, 2025CareRx Corporation announced that they will report Q1, 2025 results at 7:00 AM, US Eastern Standard Time on May 07, 2025
お知らせ • Mar 25CareRx Corporation, Annual General Meeting, Jun 05, 2025CareRx Corporation, Annual General Meeting, Jun 05, 2025.
お知らせ • Feb 26CareRx Corporation to Report Q4, 2024 Results on Mar 05, 2025CareRx Corporation announced that they will report Q4, 2024 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2025
Reported Earnings • Nov 10Third quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.025 loss in 3Q 2023)Third quarter 2024 results: CA$0.006 loss per share (improved from CA$0.025 loss in 3Q 2023). Revenue: CA$92.8m (down 1.0% from 3Q 2023). Net loss: CA$360.0k (loss narrowed 75% from 3Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Oct 31CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024CareRx Corporation announced that they will report Q3, 2024 results at 7:00 AM, Eastern Standard Time on Nov 08, 2024
お知らせ • Sep 05CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024CareRx Corporation announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024. Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto.
Reported Earnings • Aug 09Second quarter 2024 earnings released: CA$0.023 loss per share (vs CA$0.033 profit in 2Q 2023)Second quarter 2024 results: CA$0.023 loss per share (down from CA$0.033 profit in 2Q 2023). Revenue: CA$92.0m (down 2.7% from 2Q 2023). Net loss: CA$1.38m (down 173% from profit in 2Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
お知らせ • Aug 02CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024CareRx Corporation announced that they will report Q2, 2024 results at 7:00 AM, US Eastern Standard Time on Aug 08, 2024
お知らせ • May 30CareRx Corporation Announces Board ChangesCareRx Corporation announced that as part of the Company's commitment to Board refreshment and to realign Board functions to match the Company's strategic focus on operational performance, Kevin Dalton, Chairman of the Board for the last six years, will be retiring as Chairman effectively immediately. Mr. Dalton will be succeeded by Jeff Watson, a current independent director of the Board. Mr. Dalton will be stepping into the role as Chair of the Compensation, Nominating and Governance Committee in place of Maria Perrella, who will continue to remain Chair of the Audit Committee. Mr. Watson has served on the Board of CareRx since 2023 and brings over three decades of experience in the healthcare industry, having most recently served as the President and CEO of Apotex from 2018 to 2023. Mr. Watson currently represents SK Capital Partners on two of their portfolio company boards for Apotex and Woodstock Sterile Solutions, and has previously served on numerous other boards, including as a board member and Chair of the Association for Accessible Medicines (AAM), Chair of the Canadian Generic Pharmaceutical Association (CGPA), and former Chair of the US Healthcare Distribution Alliance's (HDA) knowledge partner, the HDA Research Foundation.
お知らせ • May 15CareRx Corporation Announces CFO TransitionCareRx Corporation announced that Andrew Mok will step down as Chief Financial Officer effective June 7, 2024, to pursue another employment opportunity. The Company is undertaking a search for a new CFO. Davide Pernarella, currently Vice President, Business Planning and Analysis at CareRx, will assume the role of Interim Chief Financial Officer following Mr. Mok's departure. Mr. Pernarella has worked at CareRx for over seven years in various roles with increasing responsibility, and has an intimate knowledge of the financial and business affairs of the Company. Prior to joining CareRx, he held roles in the Transaction Services and Assurance groups at KPMG Canada. Mr. Pernarella is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Commerce degree from the Rotman School of Management at the University of Toronto.
Reported Earnings • May 12First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.039 loss in 1Q 2023)First quarter 2024 results: CA$0.009 loss per share (improved from CA$0.039 loss in 1Q 2023). Revenue: CA$89.7m (down 1.8% from 1Q 2023). Net loss: CA$517.0k (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
お知らせ • Mar 15CareRx Corporation, Annual General Meeting, May 28, 2024CareRx Corporation, Annual General Meeting, May 28, 2024.
お知らせ • Mar 08CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023CareRx Corporation reported goodwill and intangible assets impairment of $710,000 for the fourth quarter ended December 31, 2023.
Reported Earnings • Mar 08Full year 2023 earnings released: CA$94.25 loss per share (vs CA$0.72 loss in FY 2022)Full year 2023 results: CA$94.25 loss per share. Revenue: CA$370.7m (down 2.9% from FY 2022). Net loss: CA$5.41m (loss narrowed 84% from FY 2022). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe.
お知らせ • Mar 01CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024CareRx Corporation announced that they will report Q4, 2023 results at 7:00 AM, US Eastern Standard Time on Mar 07, 2024
New Risk • Nov 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$9.1m net loss in 2 years). Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€51.9m market cap, or US$57.0m).
New Risk • Nov 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 25% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$9.1m net loss in 2 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€62.6m market cap, or US$66.8m).
Reported Earnings • Nov 10Third quarter 2023 earnings released: CA$0.025 loss per share (vs CA$0.038 loss in 3Q 2022)Third quarter 2023 results: CA$0.025 loss per share (improved from CA$0.038 loss in 3Q 2022). Revenue: CA$93.8m (down 3.7% from 3Q 2022). Net loss: CA$1.44m (loss narrowed 19% from 3Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Nov 02CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023CareRx Corporation announced that they will report Q3, 2023 results at 7:00 AM, US Eastern Standard Time on Nov 08, 2023
Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: CA$0.033 (vs CA$0.53 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.033 (up from CA$0.53 loss in 2Q 2022). Revenue: CA$94.5m (down 2.5% from 2Q 2022). Net income: CA$1.88m (up CA$27.0m from 2Q 2022). Profit margin: 2.0% (up from net loss in 2Q 2022). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
お知らせ • Aug 04CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023CareRx Corporation announced that they will report Q2, 2023 results at 7:00 AM, US Eastern Standard Time on Aug 10, 2023
Board Change • Jun 08Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 07Carerx Corporation Announces Director ChangesCareRx Corporation appointed Puneet Khanna and Jeff Watson as directors. Company announced that Matt Hills did not stand for re-election.
Reported Earnings • May 10First quarter 2023 earnings released: CA$0.039 loss per share (vs CA$0.059 loss in 1Q 2022)First quarter 2023 results: CA$0.039 loss per share (improved from CA$0.059 loss in 1Q 2022). Revenue: CA$91.4m (down 1.9% from 1Q 2022). Net loss: CA$2.15m (loss narrowed 22% from 1Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 12Forecast breakeven date pushed back to 2025The 8 analysts covering CareRx previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 76% per year to 2024. The company is expected to make a profit of CA$1.96m in 2025. Average annual earnings growth of 86% is required to achieve expected profit on schedule.
Reported Earnings • Mar 10Full year 2022 earnings released: CA$0.72 loss per share (vs CA$0.65 loss in FY 2021)Full year 2022 results: CA$0.72 loss per share (further deteriorated from CA$0.65 loss in FY 2021). Revenue: CA$381.7m (up 45% from FY 2021). Net loss: CA$34.4m (loss widened 51% from FY 2021). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 19CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,963,000 Price\Range: CAD 2.7 Discount Per Security: CAD 0.162
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 10Third quarter 2022 earnings released: CA$0.038 loss per share (vs CA$0.11 loss in 3Q 2021)Third quarter 2022 results: CA$0.038 loss per share (improved from CA$0.11 loss in 3Q 2021). Revenue: CA$97.4m (up 37% from 3Q 2021). Net loss: CA$1.78m (loss narrowed 55% from 3Q 2021). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 16Second quarter 2022 earnings released: CA$0.53 loss per share (vs CA$0.28 loss in 2Q 2021)Second quarter 2022 results: CA$0.53 loss per share (down from CA$0.28 loss in 2Q 2021). Revenue: CA$96.9m (up 95% from 2Q 2021). Net loss: CA$25.1m (loss widened 196% from 2Q 2021). Over the next year, revenue is forecast to grow 7.5%, compared to a 7.7% growth forecast for the Consumer Retailing industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Jun 08President recently sold €171k worth of stockOn the 1st of June, David Murphy sold around 50k shares on-market at roughly €3.41 per share. This was the largest sale by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.
Breakeven Date Change • May 13Forecast breakeven date pushed back to 2024The 7 analysts covering CareRx previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 69% per year to 2023. The company is expected to make a profit of CA$2.40m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
Board Change • May 03Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Mar 19Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: CA$0.65 loss per share (up from CA$0.90 loss in FY 2020). Revenue: CA$262.6m (up 62% from FY 2020). Net loss: CA$22.7m (loss widened 25% from FY 2020). Revenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 46%, compared to a 7.0% growth forecast for the retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 11Third quarter 2021 earnings released: CA$0.11 loss per share (vs CA$0.28 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$71.3m (up 56% from 3Q 2020). Net loss: CA$3.93m (loss narrowed 39% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 9 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$3.86m in 2022. Average annual earnings growth of 124% is required to achieve expected profit on schedule.
Reported Earnings • Aug 11Second quarter 2021 earnings released: CA$0.28 loss per share (vs CA$0.75 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$49.7m (up 25% from 2Q 2020). Net loss: CA$8.49m (loss narrowed 40% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Executive Departure • Jun 08Director Lyle Oberg has left the companyOn the 5th of June, Lyle Oberg's tenure as Director ended after 1.5 years in the role. We don't have any record of a personal shareholding under Lyle's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 2.88 years.
Executive Departure • Jun 08Director Peter Brown has left the companyOn the 5th of June, Peter Brown's tenure as Director ended after less than a year in the role. We don't have any record of a personal shareholding under Peter's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 2.88 years.
Breakeven Date Change • May 14Forecast to breakeven in 2022The 7 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2021. The company is expected to make a profit of CA$880.5k in 2022. Average annual earnings growth of 107% is required to achieve expected profit on schedule.
Reported Earnings • May 14First quarter 2021 earnings released: CA$0.21 loss per share (vs CA$0.37 profit in 1Q 2020)The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$44.9m (up 47% from 1Q 2020). Net loss: CA$5.87m (down 209% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 2% per year.
Reported Earnings • Mar 12Full year 2020 earnings released: CA$0.90 loss per share (vs CA$4.16 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$162.2m (up 30% from FY 2019). Net loss: CA$18.2m (loss narrowed 60% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 15% per year.
Analyst Estimate Surprise Post Earnings • Mar 12Revenue misses expectationsRevenue missed analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 29%, compared to a 1.6% growth forecast for the Consumer Retailing industry in Germany.
Is New 90 Day High Low • Feb 13New 90-day high: €3.16The company is up 17% from its price of €2.70 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.48 per share.
お知らせ • Feb 04+ 1 more updateCareRx Corporation announced that it has received CAD 6.244997 million in funding from Yorkville Asset Management Inc., and other investorOn February 3, 2021, CareRx Corporation (TSX:CRRX) closed the transaction. The company issued 1,469,411 shares for gross proceeds of CAD 6,244,996.75 in the transaction.
お知らせ • Jan 28+ 1 more updateCareRx Corporation announced that it expects to receive CAD 4.999998 million in funding from Yorkville Asset Management Inc., and another investorCareRx Corporation (TSX:CRRX) announced a non-brokered private placement of 1,176,470 common shares at a price of CAD 4.25 per share for gross proceeds of CAD 4,999,998 on January 27, 2021. The transaction will include participation from certain funds managed by returning investor Yorkville Asset Management Inc. and returning individual investor Jack Shevel. The transaction is expected to close on or about February 3, 2021 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange.
Is New 90 Day High Low • Jan 28New 90-day high: €2.90The company is up 14% from its price of €2.54 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.22 per share.
Is New 90 Day High Low • Dec 15New 90-day low: €2.22The company is down 21% from its price of €2.80 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.13 per share.
お知らせ • Dec 03CareRx Corporation Enters Multi-Year Pharmacy Services Agreement with an Ontario- Based Seniors Home OperatorCareRx Corporation announced that it has entered into a multi-year pharmacy services agreement with an Ontario- based seniors home operator. The new contract, which commences in January 2021, will add approximately 1,100 new retirement and long-term care residents across 13 seniors housing communities, and is expected to be serviced through CareRx's existing infrastructure.
Is New 90 Day High Low • Nov 27New 90-day low: €2.44The company is down 10.0% from its price of €2.72 on 28 August 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.14 per share.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue misses expectationsRevenue missed analyst estimates by 0.6%. Over the next year, revenue is forecast to grow 35%, compared to a 2.3% growth forecast for the Consumer Retailing industry in Germany.
Reported Earnings • Nov 07Third quarter 2020 earnings released: CA$0.28 loss per shareThe company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$45.6m (up 45% from 3Q 2019). Net loss: CA$6.41m (loss widened 146% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 33% per year.
お知らせ • Nov 03CareRx Corporation Announces Appointment of Puneet Khanna as Senior Vice President, Corporate DevelopmentCareRx Corporation announced that Puneet Khanna has joined the company as Senior Vice President, Corporate Development. Most recently, Mr. Khanna was Chief Executive Officer of MED e-care Healthcare Solutions Inc.
お知らせ • Oct 29CareRx Corporation to Report Q3, 2020 Results on Nov 05, 2020CareRx Corporation announced that they will report Q3, 2020 results at 5:00 PM, Eastern Standard Time on Nov 05, 2020
Recent Insider Transactions • Oct 01Insider recently bought €56k worth of stockOn the 29th of September, Ryan Stempfle bought around 20k shares on-market at roughly €2.78 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €55k more in shares than they have sold in the last 12 months.
お知らせ • Aug 01CareRx Corporation to Report Q2, 2020 Results on Aug 06, 2020CareRx Corporation announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020
お知らせ • Jul 30Centric Health Corporation (TSX:CHH) completed the acquisition of Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others.Centric Health Corporation (TSX:CHH) entered into a share purchase agreement to acquire Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others for CAD 35.4 million on March 23, 2020. As per the terms, consideration will be payable in CAD 8 million of cash and issuance of 125 million common shares at closing. The consideration also includes CAD 8 million of deferred consideration, comprised of CAD 4 million of deferred consideration due 12 months following closing, and CAD 4 million of consideration payable under a vendor take-back note due 18 months following closing, each of which is to be paid in cash or in certain circumstances common shares and an earn-out consideration of up to CAD 5 million payable in cash if certain performance targets are achieved over the next two years. Centric Health entered into binding commitment letters with Crown Capital Partners Inc. and Yorkville Asset Management Inc. pursuant to which Crown Capital and Yorkville are expected to advance credit facilities up to CAD 42 million to Centric Health to refinance its existing senior and subordinated credit facilities and fund the cash closing price of the transaction, CAD 7 million will be used for acquisition. In the event the transaction does not close in certain circumstances, a termination fee of CAD 1 million may be payable by the Centric Health in cash or, in certain circumstances, common shares. Bruce Moody and the Remedy's Rx Specialty Pharmacy team will join to the Centric. As part of the Transaction, Moody will receive the right to nominate two Directors to the Centric's Board of Directors under certain circumstances and will be entitled to other customary governance rights, including pre-emptive rights and registration rights. RHI generated revenue of approximately CAD 60 million for the 12-month period ended September 30, 2019. The transaction is subjected to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals and the consent of Centric Health shareholders. Under applicable Toronto Stock Exchange policies, the Centric Health is required to obtain shareholder approval for the transaction. As of April 23, 2020, Centric Health Corporation has obtained conditional approval of the transaction from the Toronto Stock Exchange and written consents from the requisite number of shareholders required to approve the transaction. The transaction is expected to close in the second quarter of 2020. As per filing on April 23, 2020, closing of the transaction will occur during the first or second week of May 2020. Origin Merchant Partners and BDO Canada LLP acted as the financial advisers to Centric Health, and NewPoint Capital Partners acted as the financial adviser to RHI. Centric Health Corporation (TSX:CHH) completed the acquisition of Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others on May 7, 2020. Jeff May will join Centric Health as its new Chief Operating Officer. Bruce Moody, Founder and former principal shareholder and Chief Executive Officer of Remedy’s RX specialty pharmacy, has been appointed as Centric Health's Board of Directors today and Peter Brown as appointed as a Board observer and will be nominated for election as a Director at Centric Health’s 2020 Annual General Meeting.